X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12646) 12646
Magazine Article (23) 23
Conference Proceeding (12) 12
Book Chapter (7) 7
Book / eBook (6) 6
Publication (5) 5
Newsletter (4) 4
Web Resource (3) 3
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11769) 11769
science & technology (8727) 8727
life sciences & biomedicine (8529) 8529
antimetabolites, antineoplastic - therapeutic use (8127) 8127
female (6736) 6736
male (6351) 6351
middle aged (5163) 5163
oncology (5013) 5013
aged (4779) 4779
antimetabolites, antineoplastic - administration & dosage (3887) 3887
adult (3682) 3682
deoxycytidine - analogs & derivatives (3383) 3383
antineoplastic combined chemotherapy protocols - therapeutic use (2835) 2835
treatment outcome (2798) 2798
fluorouracil - therapeutic use (2727) 2727
antimetabolites, antineoplastic - adverse effects (2610) 2610
deoxycytidine - therapeutic use (2289) 2289
chemotherapy (2257) 2257
animals (2052) 2052
cancer (2039) 2039
fluorouracil - administration & dosage (1721) 1721
antimetabolites, antineoplastic - pharmacology (1687) 1687
pharmacology & pharmacy (1675) 1675
aged, 80 and over (1617) 1617
combined modality therapy (1333) 1333
deoxycytidine - administration & dosage (1268) 1268
gemcitabine (1240) 1240
prognosis (1227) 1227
pancreatic neoplasms - drug therapy (1156) 1156
mice (1126) 1126
retrospective studies (1089) 1089
survival analysis (1069) 1069
care and treatment (1057) 1057
neoplasm staging (1055) 1055
adenocarcinoma - drug therapy (1053) 1053
hematology (1033) 1033
medicine & public health (1026) 1026
antineoplastic agents - therapeutic use (1021) 1021
survival rate (1021) 1021
colorectal neoplasms - drug therapy (1012) 1012
chemotherapy, adjuvant (1007) 1007
drug administration schedule (975) 975
capecitabine (968) 968
disease-free survival (960) 960
cell line, tumor (949) 949
deoxycytidine - adverse effects (923) 923
drug combinations (922) 922
methotrexate - therapeutic use (861) 861
5-fluorouracil (860) 860
fluorouracil - adverse effects (838) 838
research (827) 827
time factors (822) 822
antineoplastic combined chemotherapy protocols - adverse effects (813) 813
fluorouracil - analogs & derivatives (808) 808
surgery (798) 798
pancreatic cancer (791) 791
antimetabolites, antineoplastic - pharmacokinetics (790) 790
dose-response relationship, drug (767) 767
follow-up studies (767) 767
abridged index medicus (760) 760
analysis (748) 748
neoplasms - drug therapy (733) 733
tegafur - therapeutic use (716) 716
lung neoplasms - drug therapy (715) 715
adolescent (714) 714
colorectal cancer (692) 692
breast neoplasms - drug therapy (690) 690
methotrexate (669) 669
cisplatin - administration & dosage (660) 660
antineoplastic agents - administration & dosage (659) 659
fluorouracil (649) 649
pancreatic neoplasms - pathology (635) 635
remission induction (635) 635
methotrexate - administration & dosage (611) 611
azacitidine - therapeutic use (610) 610
oxonic acid - therapeutic use (610) 610
stomach neoplasms - drug therapy (609) 609
child (597) 597
health aspects (590) 590
antineoplastic agents (585) 585
drug resistance, neoplasm (564) 564
drug therapy (559) 559
prospective studies (551) 551
fluorouracil - pharmacology (547) 547
administration, oral (542) 542
apoptosis (525) 525
antimitotic agents (520) 520
gastroenterology & hepatology (516) 516
colorectal neoplasms - pathology (514) 514
infusions, intravenous (508) 508
apoptosis - drug effects (506) 506
hematology, oncology and palliative medicine (504) 504
risk factors (502) 502
clinical trials as topic (495) 495
radiotherapy (493) 493
disease progression (487) 487
adenocarcinoma - pathology (480) 480
pharmacology/toxicology (480) 480
neoplasm metastasis (478) 478
tumors (472) 472
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11412) 11412
Japanese (813) 813
French (245) 245
German (185) 185
Chinese (105) 105
Italian (84) 84
Russian (79) 79
Spanish (78) 78
Dutch (22) 22
Polish (18) 18
Portuguese (18) 18
Hungarian (15) 15
Korean (15) 15
Czech (11) 11
Norwegian (7) 7
Bulgarian (6) 6
Lithuanian (6) 6
Ukrainian (6) 6
Danish (5) 5
Hebrew (5) 5
Swedish (5) 5
Finnish (4) 4
Romanian (3) 3
Serbian (3) 3
Croatian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of oncology, ISSN 1569-8041, 11/2012, Volume 23, Issue 11, pp. 2799 - 2805
Sorafenib is an oral anticancer agent targeting Ras-dependent signaling and angiogenic pathways. A phase I trial demonstrated that the combination of... 
phase III randomized trial | gemcitabine | sorafenib | advanced pancreatic cancer | Advanced pancreatic cancer | Gemcitabine | Sorafenib | Phase III randomized trial | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Aged, 80 and over | Placebos | Adult | Deoxycytidine - adverse effects | Female | Double-Blind Method | Deoxycytidine - administration & dosage | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Niacinamide - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Ribonucleotide Reductases - antagonists & inhibitors | Antimetabolites, Antineoplastic - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2008, Volume 9, Issue 3, pp. 215 - 221
Journal Article
The lancet oncology, ISSN 1470-2045, 12/2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 07/2013, Volume 14, Issue 8, pp. 749 - 759
Summary Background Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the population in which most benefit is derived is uncertain... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Fluorouracil - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Colorectal Neoplasms - enzymology | Camptothecin - therapeutic use | Drug Administration Schedule | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | United Kingdom | Chi-Square Distribution | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Drug Resistance, Neoplasm - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Clinical trials | Care and treatment | Antineoplastic agents | Colorectal cancer | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 08/2013, Volume 31, Issue 23, pp. 2895 - 2902
Journal Article
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 12, pp. 1125 - 1133
... of patients with advanced non-small-cell lung cancer (NSCLC). The current recommendation is to use a platinum-based two-drug regimen as first-line therapy. Despite... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vaccinia virus - genetics | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Cancer Vaccines - therapeutic use | Interleukin-2 - immunology | Time Factors | Adult | Female | Chemotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung - pathology | Risk Assessment | Deoxycytidine - administration & dosage | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Cancer Vaccines - adverse effects | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Non-Small-Cell Lung - immunology | Disease-Free Survival | Interleukin-2 - genetics | Carcinoma, Non-Small-Cell Lung - therapy | Lung Neoplasms - immunology | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mucin-1 - immunology | Vaccines, Synthetic | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Mucin-1 - genetics | Index Medicus | Interleukin-2 | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Life Sciences | Cancer Vaccines | Membrane Glycoproteins | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Mucin-1 | Vaccinia virus | Deoxycytidine | Antimetabolites, Antineoplastic | Cancer
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 2004, Volume 109, Issue 25, pp. 3122 - 3131
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2013, Volume 369, Issue 18, pp. 1691 - 1703
Journal Article